Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Moderna, Inc. (NASDAQ:MRNA) will release earnings for its third quarter before the opening bell on Friday, Nov. 6.

Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss of $1.25 per share, versus a loss of 51 cents per share in the year-ago period. The consensus estimate for MRNA’s quarterly revenue is $890.22 million. It reported $1.02 billion last year, according to Benzinga Pro.

On Thursday, Moderna  announced that Health Canada has authorized mFLUSIVA and mCOFLU for adults 50 years of age and older.

Shares of Moderna dipped 6.6% to close at $241.46 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

• William Blair analyst Myles Minter downgraded the stock from Outperform to Market Perform on Oct. 27, 2026. This analyst has an accuracy rate of 64%.
• Piper Sandler analyst Edward Tenthoff maintained the stock with an Overweight rating and increased the price target from $167 to $230 on Oct. 26, 2026. This analyst has an accuracy rate of 60%.
• TD Cowen analyst Tyler Van Buren maintained the stock with a Hold rating and boosted the price target from $40 to $90 on Oct. 21, 2026. This analyst has an accuracy rate of 53%.
• Goldman Sachs analyst Salveen Richter maintained a Neutral rating and raised the price target from $120 to $137 on Oct. 15, 2026. This analyst has an accuracy rate of 64%.
• Morgan Stanley analyst Terence Flynn maintained the stock with an Equal-Weight rating and raised the price target from $89 to $95 on Oct. 7, 2026. This analyst has an accuracy rate of 74%.

Considering buying MRNA stock? Here’s what analysts think:

Photo via Shutterstock